Clinical Trials in the EU / 2026-526336-39-00
Authorised, recruiting
Phase III
A Phase III, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Once-Daily Oral ASC30 in Adult Participants with Obesity or Overweight with Type 2 Diabetes Mellitus (AURORA-2)
2026-526336-39-00 · tracked via the Priya Life Science EU tracker
Condition studied
Obesity or Overweight with Type 2 Diabetes Mellitus
Investigational medicinal product(s)
ASC30 Placebo Tablets A1 (oval-shaped tablets)ASC30ASC30 Placebo Tablets A1 (Round biconvex tablets)
Eligibility
Primary endpoint
From baseline to Week 72 • Percent change in body weight
Endpoint detail
From baseline to Week 72 •Change in waist circumference (cm), From baseline to Week 72 • Change in SBP (mmHg) • Percent change in fasting - non-HDL cholesterol - triglycerides
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View 2026-526336-39-00 on CTIS ↗ ← All trials in the EU